WiQo has entered a strategic partnership with Archimed to accelerate its growth in the aesthetic healthcare market, with the founders retaining a significant stake in the company.

Target Information

Established in 1995 and headquartered in Muggia, Italy, WiQo is a pioneer in the field of dermatology. The company's flagship product, PRX-T33, is recognized as the world's only needle-free chemical stimulation treatment designed for skin rejuvenation. WiQo was founded by Dottoressa Castellana and her husband, stemming from over two decades of dermatological expertise. The company’s innovative offerings are available in more than 45 countries across five continents and are utilized by approximately 40,000 skin care professionals, including dermatologists, plastic surgeons, aesthetic physicians, and operators of medical spas.

With a strong emphasis on research and development, WiQo is committed to providing effective solutions for skin rejuvenation. The company's dedication to innovation and quality has positioned it as a leader in the aesthetics market, appealing to a diverse clientele of healthcare professionals seeking advanced treatment options for their patients.

Industry Overview

The global aesthetics market, particularly in Europe, has experienced significant growth over recent years. With increasing consumer awareness about skincare and aesthetic treatments, the